Doctored safety data around FibroGen anemia drug draws SEC inquiry March 2, 2022 San Francisco Biotechnology Network News News Comments Off on Doctored safety data around FibroGen anemia drug draws SEC inquiry The SEC investigation into roxadustat's pooled cardiovascular data is the latest in a string of bad news for the drug. Click to view original post